Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 13, 2022 1:00pm

88 Views

Post# 35168852

RE:RE:RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

Take notice on how Nimbus Therapeutics spun off this one drug into a separate subsidiary that was acquired by Takeda for US$4 Billion, so that Nimbus Therapeutics as the parent company, remained intact.

This further suggests that ONCY is seeking to have the entire company acquired as a single entity rather than have pelareorep licensed in a piece-meal fashion to seperate Big Pharma interests. Such an exclusive acquisition deal enhances the value of pelareorep for the buyer.

<< Previous

Bullboard Posts

Next >>

Catch up with companies that got a Stanley Cup Playoffs boost